Figure A4.

Antitumour responses in PDX models with non-truncating ATM mutations and high ATM IHC H scores (greater than 5). (a) Representative tumour growth curves in the presence of LI6622 with I709I ATM splice site mutations, (b) representative tumour growth curves in the CR2506 model with the R3008H missense ATM mutation, and (c) representative tumour growth curves in the CR3280 model with the E2444K missense ATM mutation following treatment with DDRi agents. AZD6738 was used at 12.5 mg/kg BID (7ON 7OFF) in combination therapy with olaparib or AZD7648 at 100 mg/kg QD. Tumour growth curves represent the geometric relative tumour volume ± SEM (n = 5, per treatment arm). Dotted lines in tumour growth curves represent the end of the dosing period. Letters and numbers in brackets indicate ATM protein change and variant allele frequency, respectively. For the ATM status, models were labelled as low (<5) and high (>5) based on the IHC ATM H score.